Cerenome, Inc. CNSY
0.80 USD +0.12 (+18.12%)
At closeNov 11, 2026, 7:30 PM EST
0.81 +0.01 +1.00%
After hours · Nov 11, 7:30 PM ET
0.68 Day range 0.9015
0.43 52-week range 19.00
- YTD
- -93.72%
- 1 year
- -94.38%
News
globenewswire.com Cerenome Appoints Director Ron Andrews as Chief Business Officer HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence,…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
benzinga.com CNSide Diagnostics Inks National In-Network Laboratory Ancillary Provider With Aetna Health Plans CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), announced today that it has entered into a national in-network laboratory ancillary
globenewswire.com Cerenome Secures National In-Network Agreement with Aetna for CNSide® Cerenome now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Curis (NASDAQ:CRIS) stock increased by 25.6% to $0.83 during Tuesday's regular session. The company's market cap stands at $1.6 million. Pasithea Therapeutics (NASDAQ:KTTA) shares increased…
benzinga.com Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company"), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence today announced that a poster presentation of…- benzinga.com Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ Cerenome, Inc. (NASDAQ:CNSY) ("Cerenome" or the "Company") today announced that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging
- benzinga.com Lake Street Maintains Buy on Cerenome, Lowers Price Target to $31 Lake Street analyst Chad Messer maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $50 to $31.
- benzinga.com Cerenome Anticipates $1.55M In Payer Billings In Q3 Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer
benzinga.com ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday Analysts raised targets for Darden, ServiceNow, Robinhood, Ibex and Workiva, while cutting targets for McDonald’s, Cerenome and Wingstop.- benzinga.com Ascendiant Capital Maintains Buy on Cerenome, Lowers Price Target to $43 Ascendiant Capital analyst Edward Woo maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $57 to $43.
benzinga.com Cerenome Enters Financing Agreement With 3i Fund For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the…
benzinga.com Cerenome Highlights REYOBIQ Clinical Data And CNSide Health Economics Findings At 2026 SNO/ASCO CNS Metastases Conference Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal…
benzinga.com Cerenome Q2 EPS $(1.31) Misses $(0.85) Estimate, Sales $411.000K Miss $1.110M Estimate Cerenome (NASDAQ:CNSY) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.85) by 54.12 percent. This is a 718.75 percent decrease over losses of $(0.16)…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million. Quanterix (NASDAQ:QTRX) shares…